Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression by Brooke, GN et al.
 1 
Mechanisms of androgen receptor activation in advanced prostate cancer: 
differential coactivator recruitment and gene expression. 
 
Brooke, G. N.1, Parker, M. G.2 and Bevan, C. L.1* 
 
1Androgen Signalling Laboratory, Department of Oncology and 2Institute of 
Reproductive and Developmental Biology, Imperial College London, London W12 
0NN, UK 
 
Mechanisms of AR activation in prostate cancer 
 
androgen receptor; prostate cancer; coactivators; antiandrogens; SARMs 
 
 
* Corresponding author. Tel. 0208 383 3784, Email charlotte.bevan@imperial.ac.uk. 
 
 2 
Abstract 
Prostate tumour growth depends on androgens; hence treatment includes androgen 
ablation and antiandrogens. Eventually tumours progress and in approximately 30% 
of patients this is associated with mutation of the androgen receptor. Several receptor 
variants associated with advanced disease show promiscuous activation by other 
hormones and antiandrogens. Such loss of specificity could promote receptor 
activation hence tumour growth in the absence of conventional ligands, explaining 
therapy failure. We aimed to elucidate mechanisms by which alternative ligands 
promote receptor activation. The three most commonly identified variants in tumours 
(with amino acid substitutions H874Y, T877A and T877S) and wild-type receptor 
showed differences in coactivator recruitment dependent upon ligand and the 
interaction motif utilized. Coexpression and knockdown of coactivators that bind via 
leucine or phenylalanine motifs, combined with chromatin immunoprecipitation and 
quantitative PCR, revealed these preferences extend to coactivator recruitment in vivo 
and affect receptor activity at the transcriptional level, with subsequent effects on 
target gene regulation. The findings suggest that mutant receptors, activated by 
alternative ligands, drive growth via different mechanisms to androgen-activated 
wild-type receptor.  Tumours may hence behave differently dependent upon any 
androgen receptor mutation present and what ligand is driving growth, as distinct 
subsets of genes may be regulated. 
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Introduction 
The growth of prostate tumours, at least initially, is dependent upon androgens, which 
exert their effects via the androgen receptor (AR). Standard treatment for non-organ 
confined prostate cancer is androgen blockade, which aims to inhibit the AR pathway 
using LHRH analogues to suppress testicular androgen secretion, often in conjunction 
with antiandrogens, which bind to AR but inhibit androgen-dependent transcription 
(Goktas & Crawford, 1999). Some antiandrogens can activate the receptor under 
certain circumstances, these are referred to as partial antiandrogens or Selective 
Androgen Receptor Modulators (SARMs) and their tissue-specific effects may be 
exploited to reduce side-effects of antiandrogen therapy (Segal et al., 2006). While 
highly successful initially, androgen blockade eventually fails and the tumour recurs 
in the androgen-depleted environment.  This advanced stage of prostate cancer is 
termed androgen-independent, although the AR signalling pathway often appears to 
be retained and important in tumour growth. A number of hypotheses have been 
proposed to explain this therapy failure, including AR amplification and loss of AR 
specificity caused by mutations of the receptor (Taplin, 2007). 
The AR is a member of the nuclear receptor superfamily and shares their 
common domain structure including two activation functions – AF1 in the N-terminus 
and AF2 in the C-terminal ligand-binding domain (LBD) (Gelmann, 2002). AF1 
appears to be the more important in terms of activity of full-length receptor (McEwan, 
2004); although in the context of chromatin it appears the contribution of AF2 may be 
greater than previously believed (McEwan, 2004; Li et al., 2007).  The LBD is 
composed of 11-12 alpha-helices, the most C-terminal of which (helix 12) moves 
upon ligand binding to enclose the ligand and form part of a coactivator-binding 
surface (Wurtz et al., 1996). Coactivators, recruited to activated receptor, alter the 
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topology of chromatin at the promoter by intrinsic or recruited histone 
acetyltransferase activity, to facilitate access for other transcription factors and/or the 
preinitiation complex.  Many coactivators, including the p160 protein SRC1, interact 
with the LBD of nuclear receptors via conserved, helical leucine-rich motifs (LxxLL, 
L=leucine and x=any amino acid (reviewed in (McKenna et al., 1999)). Recently the 
AR LBD has also been demonstrated to interact with similar phenylalanine-rich 
motifs (Hsu et al., 2003; Dubbink et al., 2004; Hur et al., 2004). However, SRC1 and 
other coactivators can also interact with and promote activity of AF1 (reviewed in 
(McEwan, 2004)). 
Mutations of the AR are rare in primary prostate tumors but increase in 
frequency in advanced disease, suggesting a role in cancer progression(Taplin et al., 
1995; Marcelli et al., 2000). Of those currently described, the majority have been 
found to cluster in the LBD (Gottlieb et al., 2004). Studies of some of these mutant 
receptors have demonstrated that such substitutions can alter the specificity of the 
ligand-binding pocket, allowing non-androgenic ligands to enter the pocket and 
activate the receptor. The first such mutation to be described was a threonine to 
alanine substitution at residue 877, which not only responds to androgens but is also 
activated by oestrogens, progestins and the antiandrogens cyproterone acetate and 
hydroxyflutamide (Veldscholte et al., 1994). The T877A substitution is the most 
commonly reported in prostate cancer and lies in helix 11 of the LBD. Helix 11 
appears to be a hotspot for somatic mutation since another point mutation causing 
substitution of the same residue with serine (T877S), and one causing a histidine to 
tyrosine substitution at nearby residue 874 (H874Y) have also been reported in 
metastatic prostate tumors (Taplin et al., 1995).  Receptors carrying these mutations 
are activated by hormones including oestradiol and progesterone (Steketee et al., 
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2002). Analysis of the 3-dimensional structure of liganded wild-type AR 
demonstrated that threonine-877 forms hydrogen bonds with the 17alpha-hydroxyl 
group of R1881 (a synthetic androgen) (Matias et al., 2000).  Substitutions of the 
smaller alanine or serine are thought to change the size and shape of the pocket thus 
allowing non-androgenic ligands to enter and to promote an active conformation.  In 
contrast, histidine-874 points away from the ligand pocket and is buried in a cavity 
between helices 11 and 12, formed when helix 12 relocates after agonist binding 
(McDonald et al., 2000).  The H874Y substitution is unlikely to cause steric 
hindrance, but it has been proposed that the more hydrophobic tyrosine side chain 
could increase the strength of interaction between helix 12 and this crevice 
(McDonald et al., 2000), enabling helix 12 to relocate to the active conformation even 
when a ligand is bound that does not fit optimally.  This appears to affect subsequent 
intra- and inter-receptor interactions since it has been shown that the H874Y mutant 
has enhanced binding to the p160 coactivators (Duff and McEwan 2005); and more 
effective binding to the FQNLF motif within AF1 that mediates a ligand dependent 
N-/C-terminal interaction, required in some circumstances for maximal AR activity 
(He et al., 2000; Askew et al., 2007). 
While the contribution of AR mutations to failure of hormone therapy in a 
subset of patients is generally accepted, and promiscuous activation of several 
variants has been reported, the mechanisms by which mutant forms are activated and 
how this influences gene expression is not fully understood. This study aimed to 
elucidate how alternative ligands promote activation of the H874Y, T877A and 
T877S mutant forms of AR, and whether this differs from activation of wild-type AR. 
Here we highlight the critical contribution of cofactor binding to aberrant activation.  
The data suggest that the wild-type and variant receptors recruit different coactivator 
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complexes dependent upon the ligand bound, and this has consequences for 
subsequent gene regulation.  Hence patterns of androgen-dependent gene 
transcription, and hence tumour growth, may differ depending on any AR mutation 
present, with possible implications for disease progression and treatment. 
 
Results 
Mutations of AR alter its transactivation profile  
Previous studies have established that the substitutions H874Y, T877A and T877S 
alter activation of AR in response to different ligands. Prior to investigating activation 
of the mutant receptors in transfected cells, we checked by immunoblotting that all 
were expressed at similar levels (not shown).  We then examined the ability of the 
receptors to activate an androgen-responsive promoter (TAT-GRE-E1B) in the 
presence of androgens, SARMs/antiandrogen and other sex steroids (progestins and 
oestradiol), to build a comprehensive transcriptional profile of these receptors with 
which to inform subsequent studies on cofactor recruitment. Activation of the reporter 
was measured across a range of ligand concentrations (Supplementary Figure 1) and 
the relative activities at maximal concentrations of each ligand are shown (Figure 1). 
It was evident that wild-type receptor is not specific for androgens, as it was also 
activated to varying degrees by the SARMs cyproterone acetate (CPA) and 
mifepristone (MIF), the progestins medroxyprogesterone acetate (MPA) and 
progesterone (P4), and oestradiol (E2) (Figure 1 and Supplementary Figure 1). 
Interestingly, while the mutant receptors had similar activity to wild-type in the 
presence of androgens (mibolerone (MIB), dihydrotestosterone (DHT) and 
androstenedione (ASD)), they exhibited enhanced activity in the presence of most of 
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the non-androgenic ligands tested. One exception was that only ARH874Y showed 
enhanced activity in the presence of mifepristone, while the other SARMs or 
“partial/mixed” antiandrogens (CPA and hydroxyflutamide, OHF) could activate all 
the mutant receptors to a significantly greater extent than ARWT. The antiandrogen 
bicalutamide (BIC) was exceptional in that it did not activate any of the receptors, 
wild-type or mutant. The other non-androgenic ligands, the progestins and oestradiol, 
showed a similar pattern to the SARMs in activating the mutant receptors to a greater 
extent than the wild-type. In summary, the mutant receptors were activated to a 
similar extent as wild-type AR by androgens, but to a greater extent than ARWT by the 
non-androgenic ligands tested except bicalutamide.  
 
AR variants have different preferences for LxxLL, FxxLY and FxxFF motifs 
dependent upon ligand bound 
Recently it has been demonstrated that AR LBD not only interacts with LxxLL motifs 
but can also bind phenylalanine-rich motifs, such as FxxLY. We therefore used a 2-
hybrid assay to study the effects of mutations and ligands on AR binding to three 
different interaction motifs - LxxLL, FxxLY or FxxFF. These motifs had previously 
been identified by phage display and interact with AR LBD in the presence of 
androgen (Hur et al., 2004).   
In the presence of androgen all the ARs were able to interact with the LxxLL, 
FxxLY and FxxFF motifs, and interaction was stronger with phenylalanine-rich 
motifs than the LxxLL motif (Figure 2, compare (b) and (c) to (a)), in accordance 
with published studies (Hur et al., 2004). In the presence of mibolerone, there was no 
significant difference in the strength of interaction of ARWT, compared to any of the 
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mutant receptors, with either FxxFF or FxxLY (Figure 2(b) and (c)).  However, 
significantly stronger binding to LxxLL was observed for all the mutants, in particular 
ARH874Y, when compared to wild-type receptor. The interaction of ARWT with the 
LxxLL motif is not specific for androgen (Figure 2(a)) with similar strength 
interactions also detected in the presence of cyproterone acetate, 
medroxyprogesterone acetate and progesterone.  In contrast, interaction of ARWT with 
the phenylalanine-rich motifs appears to be more androgen specific, with strong 
interaction in the presence of all the androgens and relatively weaker interactions in 
the presence of oestradiol and progesterone.  
The mutant ARs interacted with the LxxLL motif in the presence of the same 
ligands as wild-type receptor (Figure 2(a)).  Interestingly, the receptors with a 
substitution at residue 877 have stronger binding to the LxxLL motif in the presence 
of cyproterone acetate and the progestins compared to the interactions induced by 
androgens.  These interactions of mutant receptors with LxxLL were also stronger 
than those evident for androgen-bound wild-type receptor.  Some striking differences 
were observed in the preference of receptors for different motifs dependent upon 
ligand.  Androgens, progesterone, MPA and cyproterone acetate promoted interaction 
of all the receptors with the LxxLL motif and hydroxyflutamide did not (Figure 2(a)). 
In contrast, neither MPA nor cyproterone acetate promoted interaction with the 
phenylalanine-rich motifs, while hydroxyflutamide promoted strong interaction of all 
the mutant, but not the wild-type, receptors with these motifs (Figure 2(b) and (c)). 
Interestingly, between the two phenylalanine-rich motifs tested, the preferential 
interaction with FxxLY>FxxFF, evident in all other situations, was reversed for the 
receptors carrying substitutions at residue 877 in the presence of hydroxyflutamide.  
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Hence the two SARMs, cyproterone acetetate and hydroxyflutamide, promote 
a mutually exclusive pattern of interaction of mutant receptors with motifs – CPA 
(and MPA) promotes interaction with leucine but not phenylalanine motifs, while 
OHF conversely promotes interaction with phenylalanine but not leucine motifs. 
 
Enhancement of AR activity by coactivators is dependent upon interaction motif 
and ligand 
To investigate whether these preferences could affect coactivator recruitment hence 
transcriptional activity of AR, the wild-type receptor and ART877A were coexpressed 
with two coactivators: ARA701-401, which interacts with AR LBD mainly via an 
FxxLF motif (Hsu et al., 2003); or SRC1, which interacts with AR LBD via LxxLL 
motifs (Bevan et al., 1999). Activation of an androgen-responsive promoter was 
measured in the presence of hydroxyflutamide and cyproterone acetate, which showed 
the most striking differences in the 2-hybrid assay (Figure 3). Neither coactivator was 
able to enhance the activity of the wild-type receptor in the presence of 
hydroxyflutamide, which was expected due to the inability of the ligand to activate 
the receptor in previous transcriptional assays (Figure 1(b)).  In the presence of the 
partial antagonist cyproterone acetate, however, SRC-1 was able to coactivate the 
receptor to a greater degree than ARA-701-401 (p<0.005).  More strikingly, we found 
that ARA701-401 was a more effective coactivator of ART877A in the presence of 
hydroxyflutamide (which promoted interaction only with phenylalanine-rich motifs) 
than in the presence of cyproterone acetate (which preferentially promoted interaction 
with the LxxLL motif). The converse was true for SRC1, correlating with the results 
from the mammalian 2-hybrid assays.  
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Differential recruitment of coactivators to promoters dependent upon ligand 
The previous experiments suggested that coactivator recruitment to AR is dependent 
upon the ligand bound.  To investigate recruitment of endogenous coactivators to 
endogenous promoters, chromatin immunoprecipitation (ChIP) analysis of two 
androgen-responsive control elements of the Kallikrein 2 (KLK2) gene – the enhancer 
(-3842bp) and promoter (-211bp) - was performed in LNCaP cells, which 
endogenously express ART877A. At both the 1-hour and 2-hour time points, we saw 
AR recruited to the enhancer and promoter in the presence of mibolerone and also the 
two SARMs cyproterone acetate and hydroxyflutamide (Figure 4), with highest 
recruitment in the presence of the androgen.  At the 1-hour time point, ARA70, 
containing a phenylalanine-rich motif, was found at the response elements after 
treatment with all three ligands.  However at the later time point the coactivator was 
only present after treatment with hydroxyflutamide and, in the case of the promoter, 
mibolerone - the ligands that promoted interaction with phenylalanine motifs.  In 
comparison SRC1, whilst always recruited in the presence of androgen, was much 
more strongly recruited to the promoter in the presence of cyproterone acetate than 
hydroxyflutamide. 
 To summarise, the recruitment of these coactivators to the regulatory regions 
of KLK2 was found to be both ligand- and response element-specific, with 
hydroxyflutamide promoting recruitment of ARA70 to a greater extent than 
cyproterone acetate and the inverse for SRC1 recruitment. These preferences were 
most pronounced at the later (2-hour) time-point. Hence ligand-specific motif 
preferences evident in the 2-hybrid assay were reflected in in vivo recruitment to 
AREs. 
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Coactivator knockdown demonstrates importance of interaction motif and 
ligand upon endogenous gene transcription 
To test the functional significance of ligand-dependent coactivator recruitment, we 
used siRNA to knock down ARA70 or SRC1 in LNCaP cells and analysed the effect 
on regulation of KLK2 in response to different ligands.  Knockdown of SRC1 was to 
the extent of 98% at the RNA and 70% at the protein level, while ARA70 was 
reduced by 89% at the RNA and 56% at the protein level (not shown).  In the 
presence of scrambled siRNA, KLK2 expression was induced in the order mibolerone 
> hydroxyflutamide > cyproterone acetate (Figure 5).  Reduced levels of either 
coactivator resulted in a general reduction in KLK2 expression induced by all of the 
ligands. SRC1 knockdown had a greater effect in the presence of cyproterone acetate 
compared to hydroxyflutamide, increasing their difference in induction from 11% to 
18%. In contrast, ARA70 knockdown had a greater effect in the presence of 
hydroxyflutamide, to the extent that the order of induction was reversed and higher 
KLK2 expression was found in the presence of cyproterone acetate. 
 
AR exhibits differential regulation of target genes dependent upon ligand bound. 
Previous experiments suggested that coactivator recruitment to AR is dependent on 
both ARE/promoter and ligand. We next investigated whether this has functional 
consequences with regard to gene regulation, i.e. whether different endogenous AR-
regulated genes exhibit altered expression patterns in the presence of different 
ligands. The LNCaP cell line was used, since ART877A responds to a variety of 
ligands, to compare the expression of KLK2, Differentiation Related Gene-1 (DRG-1), 
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and Cyclin Dependent Kinases 2 and 4 (CDK2 and CDK4) (Figure 6).  Both KLK2 
and CDK2 were found to be upregulated by all of the ligands tested, but had the 
highest levels of transcription in the presence of mibolerone.  Interestingly, CDK4 
was found to be only upregulated by the antiandrogens.  In contrast, the regulation of 
DRG1 is much more androgen specific, with only modest activation in response to 
hydroxyflutamide compared to that evident for mibolerone. 
 
Discussion 
The ability of ligand binding to nuclear receptors to promote recruitment of 
coactivators is well established (McKenna et al., 1999), but recruitment may also be 
affected by promoter context (Rogatsky et al., 2001) and by mutations that influence 
the function of the receptor (Duff & McEwan, 2005).  In this study of AR variants we 
have demonstrated explicitly that each of these aspects impinges on coactivator 
recruitment, ultimately resulting in altered expression of endogenous hormone-
responsive genes. To illustrate this we used AR variants that have been found to be 
associated with advanced prostate cancer, carrying somatic mutations in helix 11 of 
the ligand-binding domain (LBD). These have been postulated to contribute to the 
progression of prostate cancer to the “androgen independent” stage, since they allow 
receptor activation, thus presumably cell division, in response to alternative ligands. 
We investigated the mechanisms of the previously described gain-of-function effect, 
using ligands including the commonly used therapeutic antiandrogens (bicalutamide, 
cyproterone acetate, hydroxyflutamide), an antiandrogen/antiprogestin (mifepristone), 
naturally occurring hormones likely to be present in patients (dihydrotestosterone, 
androstenedione, oestradiol, progesterone), and strong synthetic steroids (mibolerone, 
medroxyprogesterone acetate). 
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 The wild-type receptor was transcriptionally active not only in the presence of 
androgens, but also substantially so (>20% maximal activity) in the presence of 
cyproterone acetate, oestradiol, mifepristone, medroxyprogesterone acetate and 
progesterone, confirming previous studies showing that high concentrations of some 
of these can activate AR (Berrevoets et al., 1993; Taplin et al., 1995; Miyamoto et al., 
1998; Kemppainen et al., 1999; Steketee et al., 2002).  We confirmed that variants 
ARH874Y, ART877A and ART877S exhibited increased activity in the presence of a range 
of non-androgenic ligands. These included antiandrogens, the only exception being 
bicalutamide.  
 The recruitment of coactivators to steroid receptors is often mediated by 
LxxLL-like or leucine motifs.  However, the AR is idiosyncratic in that it appears to 
interact preferentially with phenylalanine-rich motifs, found in several AR 
coactivators including ARA70, FHL2 and gelsolin (Hsu et al., 2003; Dubbink et al., 
2004; Hur et al., 2004; van de Wijngaart et al., 2006). We therefore next looked at 
whether the mutant receptors showed altered relative affinity for different interaction 
motifs in the presence of alternative ligands. It was notable that the mutant receptors 
all interacted more strongly than ARWT with an LxxLL motif in the presence of 
androgen, as previously shown for ARH874Y (Duff & McEwan, 2005; Askew et al., 
2007). Indeed the mutants were able to interact with this motif more strongly even in 
the presence of progestins and cyproterone acetate than did wild-type receptor in the 
presence of a potent androgen. Striking differences were found in the interactions 
between the ARs and either a leucine motif or a phenylalanine motif. In the presence 
of medroxyprogesterone acetate and cyproterone acetate, for example, all the mutant 
receptors interacted with the LxxLL motif whereas no interaction was detected 
between any receptor and the FxxFF or FxxLY motifs.  In the presence of 
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hydroxyflutamide the reverse was found for mutant receptors, with interaction only 
evident between these and the phenylalanine motifs. A similar trend was reported for 
ART877A by Ozers et al. who showed, using fluorescence resonance energy transfer, 
that cyproterone acetate antagonized its interaction with an FxxLF-containing peptide, 
whilst promoting its interaction with an LxxLL-containing peptide (Ozers et al., 
2007). 
 Comparison of the structure of AR LBD in complex with and without LxxLL 
and FxxLF motifs revealed that the interaction site for such motifs is an L-shaped 
hydrophobic cleft, comprised of three distinct subsites that bind the hydrophobic 
groups found in cognate peptides (Estebanez-Perpina et al., 2005).  Conserved 
charged residues at either end of the cleft, Lys720 and Glu897, form a ‘charge 
clamp’.  The main chain atoms at either end of the FxxLF motif form electrostatic 
interactions with both charge clamp residues.  In contrast, the LxxLL motif forms 
hydrogen bonds with only one - Lys720 (Hur et al., 2004). Previous studies using 
computer modeling of AR LBD in complex with androgen or SARMs, that were 
complete agonists in transcriptional assays, showed that these ligands had distinct 
effects on the size and shape of the coactivator cleft and the distance between the 
charge clamp residues (Kazmin et al., 2006). Kazmin et al. proposed that ligand-
dependent interactions identified by peptide phage display could be explained by the 
different conformations formed. Similarly, we hypothesize that the ligand- and 
mutation-dependent differences in motif preference identified here are as a result of 
distinct receptor conformations, and the alternative bonds made between the leucine- 
or phenylalanine-rich motifs and the coactivator groove (i.e. interaction with one or 
both of the charge clamp residues). 
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Having found that various ligands promote distinct interactions with motifs, 
the logical conclusion was that this would extend to differential coactivator 
recruitment. In support of this, enhancement of AR activity by SRC1 (interacts with 
the LBD via LxxLL motifs) or ARA701-401 (interacts via a phenylalanine-rich motif) 
varied dependent upon the ligand bound. Our hypothesis is that these coactivator-
specific effects are due to their differential recruitment to the LBD.  To determine the 
contribution of different coactivators to activation of endogenous gene expression by 
various ligands, we first investigated their occupancy of the endogenous KLK2 
enhancer and promoter in LNCaP cells, i.e. in the presence of endogenous ART877A. 
The first point of note was that mibolerone promoted the strongest interaction of AR 
with these regulatory sequences, and cyproterone acetate and hydroxyflutamide an 
equal, weaker interaction, correlating with levels of mRNA expression induced by 
these ligands. Next, in agreement with our interaction and reporter assays, we saw 
ARA70 recruited in the presence of hydroxyflutamide and, in the case of the 
promoter, mibolerone, conditions under which it was able to coactivate AR activity 
and interact with ART877A via a phenylalanine-rich motif. Conversely cyproterone 
acetate treatment (promoted LxxLL interaction and coactivation by SRC1) resulted in 
promoter occupancy by the LxxLL-containing coactivator SRC1. Interestingly, some 
differences between cofactor recruitment to the enhancer and promoter were evident.  
In particular, at the 2-hour time point ARA70 was recruited to the enhancer only in 
the presence of hydroxyflutamide, whereas it was additionally recruited to the 
promoter in the presence of mibolerone. One possible explanation for this is that 
cofactors are known to cycle on and off promoters with varying periodicity (Metivier 
et al., 2003),  and we hypothesise that response element context and/or ligand may 
affect said periodicity. Overall, however, ARE occupancy by endogenous coactivators 
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showed similar preferences in the presence of alternative ligands to those proposed by 
our in vitro interaction studies. That this can alter gene expression in vivo was shown 
by the fact that reducing levels of ARA70 and SRC1 had opposite effects on AR 
activation by hydroxyflutamide versus cyproterone acetate.  
These findings have clinical and diagnostic implications. Both SRC1 and 
ARA70 are expressed in human prostate cancer cell lines and in normal prostate, in 
the luminal epithelial cells that also express AR (Gregory et al., 2001; Linja et al., 
2001; Hu et al., 2004; Powell et al., 2004; Agoulnik et al., 2005). There is both in 
vitro and in vivo evidence that SRC1 is required for optimal androgen signalling and 
growth in the prostate, since knockdown of SRC1 attenuated growth and androgen-
dependent gene expression in androgen-sensitive prostate cancer cell lines (Agoulnik 
et al., 2005), and SRC1-null mice exhibit attenuation of androgen-stimulated prostatic 
growth (Xu et al., 1998). Although we saw that knockdown of ARA70 had more 
effect on KLK2 expression than SRC1 knockdown, implying that ARA70 may be 
more important in AR signalling in vivo, the relatively weak effect of SRC1 
knockdown could be due to functional redundancy between it and the highly related 
p160 coactivators, TIF2 and AIB1. This possibility is supported by study of the 
SRC1-null mouse, where increased levels of TIF2 mRNA were found in hormone-
responsive tissues and hypothesised to compensate for loss of SRC1, resulting in only 
relatively minor hormone resistance being evident in the animals (Xu et al., 1998). 
Alterations in cofactor levels is often cited as a potential mechanism for 
progression of prostate tumours to the hormone-refractory stage, but studies 
investigating differences in cofactor levels between tumour and normal or benign 
tissue are often inconclusive or even contradictory (reviewed in (Chmelar et al., 
2007)). At the protein level, several studies have shown a link between increased 
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SRC1 expression and prostate cancer progression, with increased expression in 
hormone-refractory tumours (Gregory et al., 2001; Maki et al., 2006) or linked to 
tumour stage/grade (Agoulnik et al., 2005). At the mRNA level, however, decreased 
or unaltered SRC1 levels in malignant versus benign prostate have been reported 
(Fujimoto et al., 2001; Linja et al., 2004; Maki et al., 2006).  Studies on expression of 
ARA70 in prostate cancer are equally contradictory with the coactivator being found 
to be both up-regulated at the protein level (Hu et al., 2004) and down-regulated at the 
RNA level (Li et al., 2002) in tumours versus benign tissue, whereas others have 
found no change in mRNA levels (Mestayer et al., 2003). In light of the current study, 
a possible explanation of the conflicting results of such studies could be differences in 
hormonal treatment regimes in the patients. Potentially, treatments could cause 
selection for tumour cells expressing certain cofactors – for example tumours from 
patients treated with hydroxyflutamide may be more prone to overexpress 
coactivators that interact with AR via phenylalanine-rich motifs, such as ARA70. 
Of course another factor in gene expression is the promoter context. We 
investigated expression of genes previously identified as androgen-regulated,  
involved in prostate differentiation (KLK2 and DRG1) and in cell cycle progression 
(CDK2 and CDK4). Similar to previous reports, KLK2 and CDK2 were found to be 
upregulated in response to androgen (Lu et al., 1997; Gregory et al., 1998; Nelson et 
al., 2002). In addition, we found both genes were also upregulated in response to the 
SARMs, cyproterone acetate and hydroxyflutamide. Evidence for regulation of CDK4 
by the androgen receptor pathway is contradictory since Lu et al. found up-regulation 
in response to androgen, whereas Gregory et al. found no effect (Lu et al., 1997; 
Gregory et al., 1998). We also found no androgen-dependent regulation of CDK4.  
Interestingly, however, the kinase was found to be significantly (although slightly) 
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up-regulated by the SARMs cyproterone acetate and hydroxyflutamide.  We found 
that DRG1 also showed differential regulation by the ligands, being strongly up-
regulated by mibolerone and only weakly by hydroxyflutamide. A previous study of 
DRG1 regulation in LNCaP cells also showed high specificity for androgens, 
although in this case SARMs were not studied (Ulrix et al., 1999). This all adds to a 
growing body of evidence supporting the notion that differential expression of steroid 
target genes is dependent upon many factors including the promoter, receptor 
interactions (both intra-receptor and with other proteins) and post-translational 
modifications (He et al., 2002; Li et al., 2003; Callewaert et al., 2004; Powell et al., 
2004). The implications go beyond differential expression of androgen responsive 
genes. The AR shares a common response element with the glucocorticoid, 
mineralocorticoid and progesterone receptors. Since different hormones have distinct 
effects, it remains unclear how a single response element can mediate distinct 
physiological effects in response to such ligands. One contributing factor is likely to 
be that differences in coactivator complexes recruited by different receptors could 
affect the rate of transcription from a given promoter under control of a given steroid 
receptor, hence be a mechanism to control receptor specificity (Li et al., 2003), and 
our data are supportive of this. 
Mutations of the AR have been found in 10-40% of cases of advanced, 
hormone independent prostate cancer (Taplin, 2007). Those that reduce ligand 
specificity, as presented here, may promote AR activation hence tumour growth in the 
absence of conventional AR ligands, explaining the failure of androgen blockade 
therapy. We have shown that receptors activated by non-androgenic ligands appear to 
behave differently to those activated by androgens, both in their mechanism of 
activation and their pattern of gene regulation. Genes differentially regulated include 
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those involved in prostate differentiation and in androgen-stimulated proliferation. 
This implies that prostate tumours may behave differently dependent upon which (if 
any) AR mutation is present and what ligand is driving growth, as alternative subsets 
of genes may be regulated.   
 
Methods 
Ligands and antibodies 
Ligands were dissolved in EtOH (VWR, Leicestershire, UK) and stored at -20°C.  
Androstenedione, cyproterone acetate, dihydrotestosterone, medroxyprogesterone 
acetate, mifepristone, 17ß-oestradiol and progesterone were from Sigma (Dorset, 
UK), mibolerone from PerkinElmer (Buckinghamshire, UK).  Bicalutamide and 
hydroxyflutamide were kind gifts from Astra-Zeneca Pharmaceuticals (Cheshire, UK) 
and Schering-Plough (Hertfordshire, UK) respectively.  Anti-AR (N-20), -SRC1 (M-
341) and -ARA70 (H-300) antibodies were from Santa-Cruz (Santa-Cruz, CA).  
 
Plasmids 
The following have been previously described: pSG5-SRC1e (Kalkhoven et al., 1998) 
and PB-PROM-LUC (Verrijdt et al., 2003). The following were kind gifts: pSVAR 
from Albert Brinkmann (Rotterdam); TAT-GRE-EIB-LUC from Guido Jenster 
(Rotterdam); pKBU-LxxLL (containing SSRGLLWDLLTKDSR), pKBU-FxxFF 
(containing SRFADFFRNEGLGSR) and pKBU-FxxLY (containing 
SRFEALYLDRVTGLHTDTSR) Gal4 DBD fusion proteins from Benjamin Beuhrer 
and Maria Sjøberg (KaroBio, Huddinge, Sweden) (Hur et al., 2004). 
Mutations encoding H874Y, T877S and T877A were introduced into residues 
503-919 of AR inserted into pBluescript (Stratagene, La Jolla, CA), by PCR 
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mutagenesis, and this fragment subcloned into pSVAR using KpnI and BamHI 
(Roche, Basel, Switzerland). pSG5-ARA701-401 was created by amplification of 
amino acids 1-401 of ARA70 from pSG5-ARA70 (Bevan et al., 1999) and insertion 
into pSG5 (Stratagene) using EcoRI and BamHI. VP16-AR fusion vectors were 
created by amplifying wild-type or mutant AR from pSVAR and inserting into 
BamH1 and XbaI sites of pVP16 (Clontech, Mountain View, CA). All plasmids were 
verified by sequencing. 
 
Cell Culture 
Cell lines were obtained from American Type Culture Collection (Manassas, VA). 
COS-1 and HeLa cells were cultured in DMEM and LNCaP in RPMI 1640 as 
described previously (Gamble et al., 2006). 
 
Transcription Assays 
COS-1 cells and HeLa cells at 60% confluence in 24-well plates were incubated for 
24 hours in androgen-depleted media. For dose response experiments, HeLa cells 
were transfected using FuGENE 6 with 100ng AR expression vector, 100ng PDM-
LAC-Z-ß-GAL and 1µg reporter per well.   For coexpression assays, COS-1 cells 
were transfected using the calcium phosphate method (Chen & Okayama, 1987) with 
50ng AR expression vector, 200ng or 400ng SRC1 expression vector or pSG5-
ARA701-401, 100ng PDM-LAC-Z-ß-GAL and 1µg luciferase reporter per well.  For 2-
hybrid assays, COS-1 cells were transfected as above with 100ng pVP16-AR (wild-
type or mutant), 100ng pKBU-LxxLL, -FxxLY or -FxxFF, 100ng of PDM-LAC-Z-β-
GAL and 1µg 5-GAL-TATA-LUC. After transfection cells were incubated with 
ligand for 24 hours before lysis, and luciferase and β-galactosidase activities 
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measured using the LucLite Plus (PerkinElmer, Waltham, MA) and Galacto-light Plus 
(Tropix, Bedford, MA) kits respectively.  
 
Chromatin Immunoprecipitation 
LNCaP cells were grown to approximately 70% and serum-starved for 72hrs.  Cells 
were treated for 1 or 2hrs with ligand (100nM mibolerone, 1µM other ligands) before 
cross-linking with formaldehyde (Sigma) for 10min at 37°C.  ChIP was performed 
using the Upstate Chromatin Immunoprecipitation kit (Upstate, Charlottesville, VA) 
following manufacturer’s instructions. DNA was recovered by phenol-chloroform 
extraction and semi-quantitative PCR performed using primers designed to anneal 
either side of an ARE in the KLK2 enhancer (For-
5’GTTGAAAGCAGACCTACTCTGGA-3’; Rev-5’-
CTGGACCATCTTTTCAAGCAT-3’) and promoter (For-5'-
GGGAATGCCTCCAGACTGAT-3'; Rev-5'-CTTGCCCTGTTGGCACCTA-3') 
(Kang et al., 2004). 
 
Coactivator knockdown 
LNCaP cells were grown to approximately 60% confluence in 6 well plates then 
changed to androgen-depleted media and transfected with (100nM final 
concentration) pools of scrambled (D-001810-10), ARA70- (L-010321-00) or SRC1-
targeting (L-005196-00) siRNA using Dharmafect 4 (Dharmacon, Northumberland, 
UK).  Cells were incubated for 72hrs with siRNA before addition of ligand and left 
for a further 24hrs before harvesting. 
 
Real-time quantitative PCR 
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LNCaP cells were grown to 60% confluence in 6 well plates for 72hrs.  Cells were 
treated with ligand (100nM mibolerone, 1µM other ligands) and incubated for a 
further 24hrs before harvesting. RNA was recovered using an RNAeasy kit with the 
additional DNAse step (Qiagen, West Sussex, UK) and reverse transcription 
performed on 2µg of RNA.  Expression of KLK2, CDK2, CDK4, DRG1 and GAPDH  
were measured using real-time quantitative PCR (ABI 7500, Applied Biosystemns, 
Foster City, CA) using FAM-labelled oligo sets (Ambion, Warrington, UK). Results 
were normalized using GAPDH data. 
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Legends to Figures 
Figure 1. Transcriptional profile of wild-type and mutant receptors. HeLa cells were 
transiently transfected with WT or mutant AR vectors, an androgen-responsive 
luciferase reporter (TAT-GRE-E1B-LUC) and ß-galactosidase expression vector 
(PDM-LAC-Z-β-GAL). Cells were treated for 24 hours with MIB and DHT at 100nM 
and all other ligands at 1µM.  Luciferase data were normalized for ß-galactosidase 
activity and expressed as a percentage of wild-type AR activity in the presence of 
100nM MIB.  Results are mean ±1SE of at least 3 independent experiments 
performed in duplicate. T-test for significance of difference to corresponding result 
for WT receptor: * p<0.01, ** p<0.001. EtOH = ethanol, MIB = Mibolerone, DHT = 
dihydrotestosterone, ASD = androstenedione, BIC = bicalutamide, CPA = 
cyproterone acetate, OHF = hydroxyflutamide, MIF = mifepristone, MPA = 
medroxyprogesterone acetate, P4 = progesterone, E2 = 17ß-oestradiol.  
 
Figure 2.  Interactions of the receptors with LxxLL, FxxLY and FxxFF motifs.  COS-
1 cells were transfected with Gal4-responsive luciferase reporter (5-GAL-LUC), ß-
galactosidase expression vector, plasmid expressing the VP16 activation domain 
fused to full length wild-type or mutant AR and plasmid expressing the Gal4 DNA-
binding domain fused to an (a) LxxLL, (b) FxxLY or (c) FxxFF peptide. Luciferase 
activity normalized as for Figure 1 and activity expressed as a percentage, with 100% 
taken as luciferase activity when VP16-ARWT coexpressed with LxxLL peptide in the 
presence of MIB. Results are mean ± 1SE of 3 independent experiments performed in 
duplicate.  *p<0.05, **p<0.005 (Student’s t-test). 
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Figure 3.  Enhancement of transcriptional activity by coactivators is ligand dependent. 
COS-1 cells were transfected with plasmids expressing wild-type or T877A mutant 
AR, ARA701-401 or SRC-1, androgen-responsive luciferase reporter vector (PB-
PROM-LUC) and β-galactosidase expression vector. Luciferase activity was 
normalized for β-galactosidase activity and expressed as percentage of wild-type AR 
activity in the presence of mibolerone and absence of coactivator.  Results are mean ± 
1SE of at least 3 independent experiments performed in duplicate. * = p<0.05, 
**P<0.005 (Student’s t-test). 
 
Figure 4. Differential recruitment of coactivators to endogenous androgen-responsive 
regulatory sequences is dependent upon agonist. Chromatin immunoprecipitation was 
performed on LNCaP cell extract as described with anti-AR, anti-ARA70 or anti-
SRC1 antibodies.  PCR was performed using primers designed to anneal either side of 
androgen response elements in the enhancer and promoter sequences respectively of 
the Kallikrein 2 (KLK2) gene. 
 
Figure 5. Knockdown of coactivators has different effects on gene expression 
dependent upon agonist. LNCaP cells were transfected with siRNA to knock down 
ARA70 or SRC1. Following 72hrs of incubation with siRNA, cells were treated as  
indicated for 24hrs before harvesting RNA.  Reverse transcription was performed and 
expression of Kallikrein 2 (KLK2) analysed by real-time quantitative PCR.  Result is 
a representative figure of 3 independent experiments and the mean of 8 PCR 
replicates ± 1SE. ** p<0.005 (Student’s t-test). 
 
Figure 6. Differential expression of target genes dependent upon the agonist bound. 
LNCaP cells were grown for 72hrs in stripped media and treated as indicated for 
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24hrs before cells were harvested, RNA extracted and cDNA created using reverse 
transcription.  Expression of Kallikrein 2 (KLK2), cyclin dependent kinases 2 and 4 
(CDK2 and CDK4) and Differentiation Related Gene-1 (DRG1) was analysed using 
real-time quantitative PCR. Result is a representative figure and the mean of 8 PCR 
replicates ± 1SE. ** p<0.005 (Student’s t-test). 
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Supplemental Figure 1 
Supplementary Figure 1. Dose response curves of the wild-type and mutant receptors in the 
presence of different ligands.  HeLa cells were transiently transfected with WT or mutant AR, a 
luciferase reporter (TAT-GRE-E1B-LUC) and a ß-galactosidase expression vector (PDM-LAC-Z-
β-GAL). Luciferase data were normalised for ß-galactosidase activity and expressed as a 
percentage of wild-type AR activity in the presence of 100nM MB.  Results are the mean ±1SE of at 
least 3 independent experiments performed in duplicate. Ligands tested were A - mibolerone (MIB), 
B - dihydrotestosterone (DHT), C - androstenedione (ASD), D - 17ß-estradiol (E2), E - mifepristone 
(MIF), F - medroxyprogesterone acetate (MPA), G - progesterone (P4), H - bicalutamide (BIC), I - 
cyproterone acetate (CPA), J - hydroxyflutamide (OHF).. 
